Clinical trial · Observational
Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）
NCT06537037CI-TRIAL-00079465recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urologic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Correlation analysis of sequencing results and body composition
- timeFrame
- 0.5 year
- description
- Conducting correlation analysis between body composition and results of multi-omics sequencing.
- measure
- Correlation analysis of sequencing results and tumor radiomic features
- timeFrame
- 0.5 year
- description
- Conducting correlation analysis between radiomic features and results of multi-omics sequencing.
Secondary outcomes (2)
- measure
- Constructing tumor microenvironment prediction model
- timeFrame
- 2 years
- description
- Constructing radiomic model to predict tumor microenvironment. The indicator is the area under the curve (AUC) of the prediction model
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027; 2. Aged \> 18 years old; 3. At least one CT scan or MRI scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria： 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than urologic cancer; 4. Unclear pathological diagnosis。
References
Publications (0)
Data not yet available
No reference posted for this study.